{"id":15005,"date":"2023-06-12T15:07:43","date_gmt":"2023-06-12T13:07:43","guid":{"rendered":"https:\/\/investmentbell.com\/?p=15005"},"modified":"2023-06-12T15:07:45","modified_gmt":"2023-06-12T13:07:45","slug":"catalent-posts-bigger-than-expected-loss-as-production-snags-persist","status":"publish","type":"post","link":"https:\/\/investmentbell.com\/ru\/news\/market-overview-news\/catalent-posts-bigger-than-expected-loss-as-production-snags-persist\/","title":{"rendered":"Catalent \u043f\u043e\u043d\u0435\u0441\u043b\u0430 \u0431\u043e\u043b\u044c\u0448\u0438\u0435, \u0447\u0435\u043c \u043e\u0436\u0438\u0434\u0430\u043b\u043e\u0441\u044c, \u0443\u0431\u044b\u0442\u043a\u0438 \u0438\u0437-\u0437\u0430 \u0441\u043e\u0445\u0440\u0430\u043d\u044f\u044e\u0449\u0438\u0445\u0441\u044f \u043f\u0440\u043e\u0438\u0437\u0432\u043e\u0434\u0441\u0442\u0432\u0435\u043d\u043d\u044b\u0445 \u043f\u0440\u043e\u0431\u043b\u0435\u043c"},"content":{"rendered":"<p>(Reuters) &#8211; Catalent (NYSE:CTLT) Inc on Monday posted a bigger-than-expected loss for the third quarter and cut its annual forecast for a second time, hurt by persistent production challenges at the contract drug manufacturer&#8217;s major facilities.<\/p>\n\n\n\n<p>The company will also amend its annual filing for 2022 to reflect a $26 million deduction caused by a revenue recognition error.<\/p>\n\n\n\n<p>Catalent had delayed its quarterly results report thrice in less than a month, pending the adjustments needed on historical financial statements related to its Bloomington operations.<\/p>\n\n\n\n<p>Shares of the company rose 3% to $40 in premarket trading.<\/p>\n\n\n\n<p>In May, Catalent said production snags at three of its facilities &#8211; Maryland, Indiana and Brussels &#8211; had driven up costs and also contributed to the delay in reporting results. Its cost-cutting plans have also been hampered by regulatory inspections and subsequent corrective actions.<\/p>\n\n\n\n<p>The company then changed the financial directors at its locations facing the biggest challenges, and named a new interim CFO in April.<\/p>\n\n\n\n<p>Catalent is yet to provide details of what was behind the production issues.<\/p>\n\n\n\n<p>The contract drug manufacturer now expects full-year revenue in the range of $4.23 billion to $4.33 billion, from a prior forecast of $4.25 billion to $4.35 billion. Analysts on average were expecting $4.3 billion, according to Refinitiv.<\/p>\n\n\n\n<p>Excluding items, it reported a third-quarter loss of $17 million, or 9 cents per share, compared with an adjusted profit of $188 million, or $1.04 per share, a year ago. Analysts on average had expected a loss of 3 cents.<\/p>\n<div class=\"rate-now\"><span id=\"rate-mypost15005\"><\/span> <span id=\"rate-points\"> 0<\/span><\/div>\n\t\t\t<script type=\"text\/javascript\">jQuery('#rate-mypost15005').raty({\n\t\t\t\thalfShow : true,\n\t\t\t\thalf: true,readOnly: true,score: 0,\n\t\t\t\tpath: \"https:\/\/investmentbell.com\/wp-content\/plugins\/userpro-rating\/images\/\"\n\t\t\t\t});<\/script>","protected":false},"excerpt":{"rendered":"<p>(Reuters) &#8211; Catalent (NYSE:CTLT) Inc on Monday posted a bigger-than-expected loss for the third quarter and cut its annual forecast for a second time, hurt by persistent production challenges at the contract drug manufacturer&#8217;s major facilities. The company will also amend its annual filing for 2022 to reflect a $26 million deduction caused by a [&hellip;]<\/p>","protected":false},"author":13,"featured_media":15006,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[89],"tags":[],"class_list":{"0":"post-15005","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-market-overview-news"},"_links":{"self":[{"href":"https:\/\/investmentbell.com\/ru\/wp-json\/wp\/v2\/posts\/15005","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/investmentbell.com\/ru\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/investmentbell.com\/ru\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/investmentbell.com\/ru\/wp-json\/wp\/v2\/users\/13"}],"replies":[{"embeddable":true,"href":"https:\/\/investmentbell.com\/ru\/wp-json\/wp\/v2\/comments?post=15005"}],"version-history":[{"count":0,"href":"https:\/\/investmentbell.com\/ru\/wp-json\/wp\/v2\/posts\/15005\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/investmentbell.com\/ru\/wp-json\/wp\/v2\/media\/15006"}],"wp:attachment":[{"href":"https:\/\/investmentbell.com\/ru\/wp-json\/wp\/v2\/media?parent=15005"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/investmentbell.com\/ru\/wp-json\/wp\/v2\/categories?post=15005"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/investmentbell.com\/ru\/wp-json\/wp\/v2\/tags?post=15005"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}